NRx Pharma Says FDA Identifies No Bioequivalence Issues In Preservative-free Ketamine Application

NRx Pharmaceuticals (NRXP) said the FDA has not identified any bioequivalence deficiencies in its Abbreviated New Drug Application for a preservative-free ketamine product, per written correspondence. This removes a material regulatory hurdle short of approval and keeps the program on track for potential commercialization, representing a modest positive catalyst for the stock. The communication is not an approval and further review steps remain.

Analysis

NRx Pharmaceuticals (NRXP) said the FDA has not identified any bioequivalence deficiencies in its Abbreviated New Drug Application for a preservative-free ketamine product, per written correspondence. This removes a material regulatory hurdle short of approval and keeps the program on track for potential commercialization, representing a modest positive catalyst for the stock. The communication is not an approval and further review steps remain.